Galectin Therapeutics (GALT) Other Non-Current Liabilities (2010 - 2026)

Galectin Therapeutics' Other Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 2090.44% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $3.0 million (up 2090.44% YoY), while the FY2025 annual figure was $4.0 million, up 4114.89% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $3.0 million, down from $4.0 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $4.0 million in Q4 2025, with the low at $94000.0 in Q1 2024.
• The 5-year median for Other Non-Current Liabilities is $341000.0 (2022), against an average of $804625.0.
• The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities sank 80.38% in 2024, then jumped 4114.89% in 2025.
• Galectin Therapeutics' Other Non-Current Liabilities stood at $214000.0 in 2022, then jumped by 101.4% to $431000.0 in 2023, then tumbled by 78.19% to $94000.0 in 2024, then surged by 4114.89% to $4.0 million in 2025, then retreated by 24.81% to $3.0 million in 2026.
• Business Quant data shows GALT's Other Non-Current Liabilities at $3.0 million in Q1 2026, $4.0 million in Q4 2025, and $1.5 million in Q2 2025.